Kura Oncology, Inc.

This early-stage trial is testing the safety and initial effectiveness of a new oral drug, ziftomenib, when given alongside the standard drug imatinib. It is for adults with advanced gastrointestinal stromal tumors (GIST) whose cancer has continued to grow despite treatment with …

This study is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and effective. It will involve 420 adults with acute myeloid leukemia (AML) who have specific genetic changes in their cancer cells. The main goals are to find the …

This is the first time a new drug called ziftomenib is being tested in people. The study aims to find a safe and effective dose for adults with advanced acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has returned or not responded to other treatments. It w…

This large, late-stage trial is testing whether adding an experimental drug called ziftomenib to standard treatments helps people with newly diagnosed acute myeloid leukemia (AML) who have specific genetic mutations. The study will enroll 1300 adults and has two parts: one for ol…

This is the first study in people testing a new cancer drug called KO-2806. It aims to find a safe dose and see if the drug can help control advanced solid tumors, including certain lung, colorectal, pancreatic, and kidney cancers. The study will test the drug by itself and combi…

This early-stage trial is testing whether adding an experimental drug called ziftomenib to standard leukemia treatments is safe and tolerable for patients. It focuses on adults with acute myeloid leukemia (AML) that has returned or not responded to prior therapy and has specific …